The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro.
N. Fatima, Y. Shen, K. Crassini, E. Iwanowicz, H. Lang, D. Karanewsky, R. Christopherson, S. Mulligan, G. Best
This study shows TR-57 is effective as a single agent and in combination with venetoclax against CLL cells in vitro, regardless of TP53 aberrations.
bioRxiv · Mar 7, 2022Cancer Biology